By Alexander Bueso
Date: Friday 24 Jul 2020
(Sharecast News) -
By Alexander Bueso
Date: Monday 23 Dec 2019
(Sharecast News) - Switzerland's Roche has bought the rights to launch and sell one of Sarepta Therapeutics's gene therapy treatments for Duchenne muscular dystrophy outside of the States, sending shares in the US-based biotechnology outfit flying in premarket trading.
By Alexander Bueso
Date: Thursday 10 Oct 2019
(Sharecast News) - Analysts at RBC reiterated their recommendation to 'buy' shares of Sarepta, expressing confidence in the efficacy of the gene therapy specialist's muscular distrophy programmes, telling clients that they believed they would "ultimately succeed".
Currency | US Dollars |
Share Price | $ 20.22 |
Change Today | $ 0.16 |
% Change | 0.80 % |
52 Week High | $143.45 |
52 Week Low | $12.88 |
Volume | 9,540,270 |
Shares Issued | 66.44m |
Market Cap | $1,343.47m |
RiskGrade | 650 |
Strong Buy | 6 |
Buy | 2 |
Neutral | 16 |
Sell | 4 |
Strong Sell | 2 |
Total | 30 |
Time | Volume / Share Price |
15:59 | 391 @ $20.22 |
15:59 | 100 @ $20.21 |
15:59 | 199 @ $20.21 |
15:59 | 100 @ $20.21 |
15:59 | 100 @ $20.21 |
You are here: research